5411.68

Less: Excise Duty

52.16

Net Sales

5359.52

b) Other Operating Income

265.39

Total Operating Income (a+b)

5624.91

a) (Increase)/decrease in
     Stock-in-trade and work in progress

(265.19)

b) Consumption of Materials

2114.11

c) Purchase of Traded Goods

621.66

d) Employee Cost

371.31

e) Depreciation

189.66

f) Other Expenditure

1426.72

g) Total

4458.27

1166.64

88.11

1254.75

23.66

1231.09

95.00

1326.09

243.50

1082.59

Share of Profit (+)/Loss(-) in Associates

-

Net Profit (+)/Loss (-) for the period (11+12)

989.57

1082.59

Paid-up Equity Share Capital
(Face Value Rs.2 per share)

160.58

Reserves excluding Revaluation
Reserves as per Balance Sheet of previous Accounting Year

5741.03

Earning per Share (Rs.)

12.32

13.69

Public Shareholding
- Number of Shares
- Percentage of Shareholding

503606049
62.72

500849336
62.38

Promoters and Promoter Group Shareholding

a) Pledged/Encumbered
     - Number of Shares
     - Percentage of shares (as a % of the total        shareholding of promoter and promoter group)
     - Percentage of shares (as a % of the total share        capital of the Company)

NIL
NIL

NIL

b) Non Encumbered
     - Number of Shares
     - Percentage of shares (as a % of the total         shareholding of promoter and promoter group)
     - Percentage of shares (as a % of the total share         capital of the Company)

295485978
100.00

36.80

1. The Company is essentially in the pharmaceutical business segment.
2. The Directors at their meeting held today recommended payment of final dividend of Rs.2 per equity share (face value Rs.2) for the year 2010-2011 amounting to Rs.160.58 crores. In September 2010, the Company paid an interim dividend of 80 paise per equity share (face value Rs.2) for the year 2010-2011.
3. The above results include results of the Company, its subsidiaries and associates and are prepared in accordance with the principles set out in Accounting Standard 21 - Consolidated Financial Statements and Accounting Standard 23 - Accounting for Investments in Associates in Consolidated Financial Statements as prescribed by the Institute of Chartered Accountants of India. The financial results of certain subsidiaries and associates have been included in the consolidated results on the basis of management accounts not reviewed by the auditors.
4. In 2003, the Company received notice of demand from the National Pharmaceutical Pricing Authority, Government of India on account of alleged overcharging in respect of certain drugs under the Drug Price Control Order. This was contested before the jurisdictional High Courts wherein it was held in favour of the Company. The orders were challenged before the Hon'ble Supreme Court by the Government. The Hon'ble Supreme Court by separate orders restored the matter to the jurisdictional High Court for interpreting the Drug Policy on the basis of directions and principles laid down by them and also restrained the Government from taking any coercive action against the Company.  The Company has been legally advised that on the basis of these orders there is no probability of demand crystallising. Hence no provision is considered necessary in respect of notice of demand aggregating to Rs.1230.28 crores (inclusive of interest) for the period July 1995 to April 2009.
5. The Audited Standalone financial results is available on the Company's website i.e.www.cipla.com. The key standalone financial information for the year 2010 - 2011 are as under: a. Turnover: Rs 6183.87 crore (previous year Rs 5411.68 crore) b. Profit before tax: Rs1151.39 crore (previous year Rs 1324.99 crore) c. Profit after tax: Rs 960.39 crore (previous year Rs 1081.49 crore)
6. The figures of the previous year have been regrouped/recast to render them comparable with the figures of the current year.
7. The Audited Consolidated Statement of assets and liabilities is as under :
   

(Rs. in crores)
Particulars	Year Ended
	31.03.2011	31.03.2010
Shareholders Funds
(a) Capital	160.58	160.58
(b) Reserves and Surplus	6692.18	5749.99
Loan Funds	571.89	5.07
Deferred Tax Liabilities	213.12	179.15
Total	7637.77	6094.79
Fixed Assets	3379.89	2695.41
Investments	590.41	246.41
Current Assets, Loans and Advances
(a) Inventories	1906.16	1512.58
(b) Sundry Debtors	1490.82	1566.63
(c) Cash and Bank balances	101.02	62.06
(d) Other current assets	0.06	4.70
(e) Loans and Advances	1161.87	1221.34
Less: Current Liabilities and Provisions
(a) Liabilities	958.08	997.97
(b) Provisions	34.38	216.37
Total	7637.77	6094.79

8. *Tax expense is inclusive of current tax, deferred tax and Minimum Alternate Tax (MAT) credit.
9. The above results after being reviewed by the Audit Committee were approved at the meeting of the Board of Directors held on 29 th June, 2011